KEENOVA THERAPEUTICS PUBLIC LIMITED COMPANY

Keenova Therapeutics Public Limited Company is a specialty-therapeutics business formed in November 2025 following the merger of Mallinckrodt and Endo and the subsequent spin-off of their generics and sterile-injectables operation as Par Health. Keenova's mission is to improve the lives of patients living with rare, stigmatised or otherwise unaddressed conditions, delivering innovative medicines across a broad therapeutic spectrum.

The company's portfolio concentrates on immunology, urology, hepatology, ophthalmology, orthopaedics and critical care, offering targeted treatments that address unmet medical needs. By leveraging the scientific expertise and global reach inherited from its parent organisations, Keenova aims to bring forward-looking therapies to patients and healthcare providers who need them most.